Breast Carcinoma
Conditions
Keywords
hypofractionated radiotherapy, Two-Stage Expander/Implant Reconstruction, breast cancer
Brief summary
Hypofractionated radiotherapy could provide more convenient treatment and had similar toxicities.However,reports of hypofractionated radiotherapy with two-stage expander/implant reconstruction are rare,Some studies have shown that hypofractionated radiotherapy had similar toxicities to conventional fractionated radiotherapy in patients with breast reconstruction. So,investigators conducted a phase II study to observe the reconstruction failure in hypofractionated radiotherapy with two-stage expander/implant reconstruction.
Detailed description
Results from a phase III randomized controlled study in China showed that Postmastectomy hypofractionated radiotherapy was non-inferior to and had similar toxicities to conventional fractionated radiotherapy in patients with high-risk breast cancer.However,reports of hypofractionated radiotherapy with two-stage expander/implant reconstruction are rare. Literatures report that reconstruction failure is a well-known complication of radiation therapy in breast cancer patients with reconstruction. Results may vary based on RT timing and technique. Some studies have shown that hypofractionated radiotherapy had similar reconstruction failure to conventional fractionated radiotherapy in patients with breast reconstruction. So,investigators conducted a phase II study to observe the reconstruction failure in hypofractionated radiotherapy with two-stage expander/implant reconstruction.
Interventions
RADIATIONhypofractionated radiotherapy
Undergo hypofractionated RT，obeserve reconstruction failure，cosmetic result and recurrence rate
Sponsors
Chinese Academy of Medical Sciences
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Pathologic diagnosis of stage I-IIIc invasive breast cancer (ductal, lobular, mammary, medullary, or ductal) ≤ T3 or N+ * negative surgery margins * positive postoperative pathologic axillary lymph nodes after neoadjuvant chemotherapy (ypN+). * Undergo mastectomy+expander+RT（hypofractionated radiotherapy）+delayed prosthesis reconstruction * Sign the informed consent form
Exclusion criteria
* T4, * axillary sentinel lymph node biopsy without axillary dissection * Recurrent breast cancer or history of prior breast radiation therapy (neck, chest wall, axilla) * Uncontrollable co-morbidities, including but not limited to active collagen vascular disease (e.g., systemic lupus erythematosus, scleroderma, or dermatomyositis), persistent or active infection, symptomatic congestive heart failure, unstable angina, mental illness incapacitating participation in this study * Pregnancy or breastfeeding * History of malignancy other than the following： (At least 5 years of tumor free survival with a very low risk of recurrence, e.g., carcinoma in situ of the cervix and basal cell or squamous cell carcinoma of the skin） * requiring bilateral breast/chest wall radiation therapy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| reconstruction failure | 12 months after the reconstructive surgery | the 1-year rate of implant removal due to serious complications (such as infection, hematoma, seromatas, prosthesis exposure, prosthesis rupture, envelope contracture, severe breast deformity, etc.) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| cosmetic result | 12 months after the reconstructive surgery | Digital photographs will be taken of each patient to facilitate thorough assessment of breast symmetry, cleavage and donor site scarring. Overall satisfaction is scored on a five-point Likert scale (1 = very unhappy, 5 = very happy). |
Other
| Measure | Time frame | Description |
|---|---|---|
| Acute and late radiotherapy toxicity | through study completion, an average of 1 year | Radiotherapy toxicity assessed by CTCAE3 and RTOG standard （e. g. acute skin toxicity, radiation pneumo nitis, etc.) |
Countries
China
Contacts
Primary ContactNing Li, MD
Outcome results
None listed